MedTrace Logo

Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

NCT04310631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2020-03-17

No results posted yet for this study

Summary

This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Conditions

  • Coats Disease

Interventions

DRUG

Ranibizumab Injection

Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Gilda Cennamo · Federico II University

  • Daniela Montorio · Federico II University

Eligibility

Min Age
19 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04310631 on ClinicalTrials.gov